| Name | Role stated in the filing | Named in |
|---|---|---|
| Fran Magee | Chief Technology Officer, Chief Technology Officer and Chief Operating Officer, Chief Technology Officer and Chief Operating Officer of the Issuer, Executive Officer | 2026-06-05, 2024-12-18, 2023-10-11, 2023-08-31, 2023-02-08 |
| Frank Cammisa, MD | Director | 2026-06-05, 2024-12-18, 2023-10-11, 2023-08-31, 2023-02-08 |
| John Viscogliosi | Director | 2026-06-05, 2024-12-18, 2023-10-11, 2023-08-31, 2023-02-08 |
| Marc Viscogliosi | Director and Chief Executive Officer of the Issuer, Executive Officer, Director | 2026-06-05, 2024-12-18, 2023-10-11, 2023-08-31, 2023-02-08 |
| Thomas Bumol, PhD | Director | 2026-06-05, 2024-12-18, 2023-10-11, 2023-08-31, 2023-02-08 |
| Jason Gallagher | Chief Commercial Officer/Chief Operations Officer, Executive Officer | 2024-12-18 |
Want the whole picture on Spine BioPharma, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Spine BioPharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Spine BioPharma, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
4 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Names and roles exactly as the filings list them: executive officers, directors and promoters. Nothing here is inferred, and a filing only lists the people it is required to.